Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders - Top-Institutions - MDSpire

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

  • By

  • Edward Koo

  • Sarah Albert

  • Benjamin Patrick

  • Meriem Henia

  • Yona Rhiwi

  • Christopher McCudden

  • Victor Jimenez Zepeda

  • Irwindeep Sandhu

  • Michael Chu

  • Hira Mian

  • Alissa Visram

  • March 26, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Plasma Cell Disorders

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Plasma Cell Disorders

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Plasma Cell Disorders

  • #4

    University of Arkansas for Medical Sciences (UAMS)
    University of Arkansas for Medical Sciences (UAMS)

    Little Rock, AR

    Key Differentiators

    • Hematology
    • Oncology
    • Plasma Cell Disorders

  • #5

    The Ottawa Hospital
    The Ottawa Hospital

    Ottawa, ON

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

  • by Edward Koo, Sarah Albert, Benjamin Patrick, Meriem Henia, Yona Rhiwi, Christopher McCudden, Victor Jimenez Zepeda, Irwindeep Sandhu, Michael Chu, Hira Mian, Alissa Visram

  • March 26, 2026

Related Content

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma